Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter.
If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion.
According to the report, some people said other unnamed suitors are also eying Seagen, a perennially speculated takeover target.
Talks have been underway for a while, the people said.
Though the people cautioned that pulling off the deal could be tricky given the heightened risk of a regulatory challenge.
WSJ also mentioned that a marketing agreement is also possible between Merck and Seagen.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.